GILD Stock Price Today (October 2026) — Gilead Sciences, Inc. Analysis & Key Metrics 2026-10-21
Gilead Sciences, Inc. (GILD) is trading at $156.51, up 2.25% today (as of October 2026). The stock continues to show sustained strength above key moving averages, attracting attention from investors looking for Healthcare growth opportunities.
- According to consensus analyst estimates, the 1-year price target is $159.85 (2.1% upside).
- Volatility is moderate (25.69% annualized), implying notable price swings for short-term traders.
- The fundamental picture, based on the latest financial filings, is nuanced: solid revenue growth (10.20% YoY) alongside competitive pressures in the Drug Manufacturers - General space.
GILD Stock Analysis: Key Metrics & Valuation (October 2026)
Concise, actionable data for investors
Gilead Sciences, Inc. - Historical Price & Volume
- Price
- Volume
- Latest price
Market Cap
Enterprise Value: $215.43B
P/E Ratio
Forward P/E: 14.80
Revenue Growth
Year over Year
Analyst Target
+2.1% upside potential
Key Investor Questions About GILD
What investors need to know before buying
Based on current market data, GILD presents a neutral technical setup with mixed signals fundamentals.
- Technicals say: Neutral (RSI 54.86)
- Fundamentals say: Mixed signals (nuanced financial profile)
GILD's growth trajectory depends on its ability to expand within the Drug Manufacturers - General sector while managing margin pressures.
- Future growth will depend on performance in core Drug Manufacturers - General operations.
- The ability to manage competitive pressures will be crucial for sustained growth.
The primary risks for GILD investors include debt exposure and competitive dynamics in the Drug Manufacturers - General industry.
- $26.25B in debt could be a headwind in a high-rate environment.
- Fierce competition from established players in Drug Manufacturers - General.
52-Week Trading Range
Over the past year, GILD stock traded between $114.02 and $160.51 and currently trades near the high end of that range. Big swings are likely unless a major catalyst emerges.
Volatility & Risk Profile
With 25.69% annualized volatility and β=0.48, the stock exhibits low sensitivity to market moves—making GILD suitable for investors comfortable with active risk management.
Institutional & Insider Ownership
High institutional ownership with low short interest suggests steadier hands and low immediate risk.
Analyst Sentiment & Price Targets
Latest News & Headlines
Recent headlines, coverage and TickZen analysis
Market news
ETFs Are Net Sellers of Gilead Sciences (GILD) on Oct. 16
ETF Activity: QQQ Outflows Offset SPY Inflows on Friday
How Investors Are Reacting To Gilead Sciences (GILD) FDA Drug Approvals
What Has Changed About Owning Gilead Stock?
All You Need to Know About Gilead (GILD) Rating Upgrade to Buy
1 Unprofitable Stock with Exciting Potential and 2 We Find Risky
Latest TickZen Insights
All insights →No TickZen article on GILD yet. Our newest analysis:
Explore More Analysis for GILD
Additional research, tools, and technical breakdowns
Stock Analyzer Report
Deep-dive automated research and stock rating report.
DCF Fair Value Calculator
Discounted cash flow model and intrinsic value projection.
AI Price Predictions
Multi-scenario price predictions and consensus targets.
Insider Activity Tracker
Track buying/selling behavior of corporate insiders.
Earnings Calendar
Track upcoming and historical corporate earnings reports.
Market Insights & Research
Read the latest analysis articles and expert research.
Earnings snapshot
Next report Oct 29, 2026 (after the close, usually)
Frequently Asked Questions
Common investor questions about Gilead Sciences, Inc.
Gilead Sciences, Inc. (GILD) is currently trading at $156.51. The RSI (14-day) is at 54.9, indicating neutral territory. Wall Street analysts have a consensus "buy" recommendation. The mean analyst price target of $159.85 implies 2.1% upside from current levels. Volatility is moderate at 25.7% annualized, meaning price movements are relatively contained. Investors should consider their risk tolerance, investment horizon, and portfolio diversification before making a decision.
Based on current valuation metrics for Gilead Sciences, Inc. (GILD): The trailing P/E ratio is not available (the company may not be profitable). The forward P/E is 14.80. Price-to-Book is 15.36. Price-to-Sales is 5.96. Valuation should be compared to Drug Manufacturers - General industry peers for context, as different sectors trade at different multiples.
Based on 26 analysts covering GILD, the consensus price target is $159.85. This represents a 2.1% upside from the current price of $156.51. The range spans from a low target of $126.00 to a high target of $180.00, reflecting varying levels of optimism among analysts. The consensus recommendation is "buy". Note: Analyst price targets are forward-looking estimates and not guarantees of future performance.
Yes, Gilead Sciences, Inc. (GILD) pays a dividend with a current yield of approximately 2.22%. The annualized dividend rate is $3.22 per share. The payout ratio is 43.5%, which is conservative and suggests the dividend is well-covered by earnings with room for future increases. The most recent ex-dividend date was Sep 15, 2026.
Key risks for Gilead Sciences, Inc. (GILD) investors include: 1. Moderate volatility (25.7% annualized)—price swings are notable. 2. Elevated debt levels (debt-to-equity of 2.23x) which could pressure margins in a rising rate environment. 3. The company is not currently profitable on a trailing basis, which creates earnings uncertainty. 4. Broader market and macroeconomic risks (interest rates, inflation, geopolitical events). 5. Drug Manufacturers - General sector-specific competitive pressures. Investors should diversify and consider their risk tolerance before investing.
Here is Gilead Sciences, Inc.'s (GILD) current debt and financial health profile: Total debt stands at $26.25B. The debt-to-equity ratio is 2.23x, which is high and could pose financial risk if earnings decline or borrowing costs increase. The current ratio is 1.27, indicating adequate short-term liquidity. The quick ratio is 0.90. The company holds $4.88B in cash and equivalents. Free cash flow is positive at $9.77B, providing a cushion for debt servicing and shareholder returns.